Loading…
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Legislative Progress
Introduced
February 21, 2025
Latest Action
February 21, 2025
Primary Sponsor
Gregory F. MurphyRepublican(NC)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 10,940 other HR bills in the 119th — cohort avg 30d
This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program. The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation. The bill's changes apply retroactively.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2026 · third_quarter · Health Issues
FY 2026 Appropriations for Agencies ---Administration for Strategic Preparedness and Response (ASPR) ---Centers for Disease Control and Prevention (CDC) ---Centers for Medicare and Medicaid (CMS) ---Food & Drug Administration (FDA) ---Health Resources and Services Administration (HRSA) ---National Institutes of Health (NIH) FY 2026 Appropriations for Specific Issues ---Alternative Funding Programs ---Antimicrobial Resistance (General) ---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---CICP ---CMMI: GLOBE and GUARD Models ---Drug Pricing ---Funding for Strategic National Stockpile ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Influenza Planning & Response ---MCM PRV Reauthorization ---Pandemic Preparedness -R&D Funding for Medical Countermeasures ---Pediatric Priority Review Voucher ---Prescription Drug User Fee Act (PDUFA) VIII Implementation ---Project Bioshield ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---Section 317 Immunization Program ---Vaccines and Infectious Diseases ---Vaccine Injury Compensation Program 340B Drug Discount Program ---H.R.5256: 340B ACCESS Act ---H.R.9504: Tax Exempt Hospital Transparency Act ---H.R.9599: SECURE 340B Act ---S.5244: SUSTAIN 340B Act ---Program Implementation & Oversight ---Rebate Models Accelerated Approval Artificial Intelligence (AI) Alternative Funding Programs Biodefense Research, Development and Procurement Issues (Non-Funding) ---Gain of function (Viral Gain of Function Research Moratorium Act, SAFE Risky Research Act) ---Implementation of BIOSECURE Act ---MCM PRV Program Reauthorization ---National Defense Authorization Act 2027 ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---Risky Research Review Act ---VICP Loopholes Biosimilars ---H.R.10628/S.5571: Biosimilars Access and Affordability Act ---S.1414: Expedited Access to Biosimilars Act ---S.1954: Biosimilar Red Tape Elimination Act ---Biosimilars Competition (General) ---Interchangeability and Pharmacy Substitution Cell & Gene Therapy ---H.R.1672: Maintaining Investments in New Innovation (MINI) Act Clinical Trial Data in China ---Next-Generation U.S. Clinical Development to Accelerate Cures - Legislative Discussion Draft Data Privacy ---H.R.8413: SECURE Data Act ---Clinical Trial Data in China ---Implementation of BIOSECURE Act Diagnostics and Personalized Medicine Regulation and Oversight Diversity & Inclusion ---H.R.3521: Clinical Trial Modernization Act ---Decentralized Clinical Trials Drug Evaluation and Review ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---FDA Hiring Flexibility Drug Importation Drug Manufacturing, Quality & Distribution ---S.3788: CLEAR Labels Act ---Advanced Manufacturing ---Compounding Pharmacies ---Drug Shortages ---Supply Chain Integrity and Traceability Drug Patenting ---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1041: Affordable Prescriptions for Patients Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1097: Interagency Patent Coordination and Improvement Act ---S.2658: Medication Affordability and Patient Integrity Act Drug Pricing ---H.R.1492/S.832: Ensuring Pathways to Innovative Cures (EPIC) Act ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act ---H.R.5391/S.2764 Protecting Patient Access to Cancer and Complex Therapies Act ---H.R.9418: Access to Innovative Treatments Act of 2026 ---S.526: Pharmacy Benefit Manager Transparency Act ---S.1097: Interagency Patent Coordination and Improvement Act ---S.1954: Biosimilar Red Tape Elimination Act ---S.3014: Ensuring Timely Access to Generics ---CMMI Authority ---Ensuring Access to Generic Medications Act ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Implementation of ORPHAN Cures Act ---International Pricing Policies ---Tariffs Efforts to Expand the Bioeconomy & Biomanufacturing ---H.R.8930: Federal Biotechnology Workforce Assessment Act ---H.R.8938: Biotechnology Workforce Alignment Act of 2026 Foreign Drug Data Protection Law ---Implementation of BIOSECURE Act Generic Drug Entry ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.1095: Stop STALLING Act ---Generic Drug Application Review Reforms ---Incentives for Generic Entry Issues Relating to Medical Research and Animal Testing ---FDA Modernization Act 3.0 Medicaid ---S.526: Pharmacy Benefit Manager Transparency Act ---Alternative Payment Arrangements for Gene Therapies ---Drug Benefit Design ---Most Favored Nation Drug Pricing Proposals ---Pricing and Rebates National Defense ---Medical Countermeasure Priority Review Voucher Reauthorization ---H.R.8800: National Defense Authorization Act for Fiscal Year 2027 National Security ---H.R.10568: Protecting Biological Data as Critical Infrastructure Act ---H.R.10569: Protecting Biotechnology and Biomanufacturing as Critical Infrastructure Act ---S.3741: Biosecurity Modernization and Innovation Act of 2026 ---Clinical Trial Data in China ---CMMI: GLOBE and GUARD Models ---Implementation of BIOSECURE Act ---International Pricing Policies ---Medical Countermeasure Priority Review Voucher Reauthorization ---NSC/OSTP priorities ---Nucleic acid synthesis security and biotechnology governance Opioid Crisis ---Non-Opioid Analgesics Orphan Drug Issues ---H.R.1414: Cameron's Law ---Implementation of ORPHAN Cures Act ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Orphan Drug Tax Credit Pandemic Preparedness ---Drug Supply Chain Management ---R&D Funding for Medical Countermeasures ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---Supply Chain Issues Precision Medicine Initiative Rare Pediatric Disease Priority Review ---H.R.10359: Priority for Pediatric Cures Act ---S.822: Scientific EXPERT Act ---Rare Disease Pilot Program Reimbursement and Coverage of Innovative Products ---H.R.5509/S.2903:SAFE STEP Act ---S.864/H.R.6423: HELP Copays Act ---Access to Innovative Treatments ---CMMI Authority ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Medicare Part B Physician-Administered Products ---National Coverage Determination ---Patient Cost-Sharing and Smoothing ---Prior Authorization Reform ---Protected Classes ---Step Therapy ---Support of Patient Premiums and Cost-Sharing Obligations ---Value-Based Contracting and Communications ---Value-Based Purchasing (VBP) Rule Vaccines and Infectious Diseases ---H.R.5509/S.2903: SAFE STEP Act ---H.R.7352/S.4875: PASTEUR Act of 2026 ---H.R.9418: Access to Innovative Treatments Act of 2026 ---H.R.9672: Vaccine Injury Compensation Modernization Act of 2026 ---Adult Immunization ---Maternal Immunization ---MCM Manufacturing & Capacity ---MCM R&D Incentives ---Monoclonal Antibody Coverage and Utilization ---Senate Discussion Draft - Vaccine Injury Protection Act ---Vaccine and Antimicrobial Resistance Product Development and Incentives ---Vaccine Injury Compensation Program ---Vaccine Safety ---Vaccine Safety Net and Vaccine Infrastructure ---Value of Vaccines and Vaccine Confidence
Client expense: $2,560,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE
2026 · third_quarter · Medicare/Medicaid
FY 2026 Appropriations for Specific Issues ---Alternative Funding Programs ---Antimicrobial Resistance (General) ---CMMI: GLOBE and GUARD Models ---Drug Pricing ---Pandemic Preparedness - R&D Funding for Medical Countermeasures ---Vaccines and Infectious Diseases 340B Drug Discount Program ---H.R.5256: 340B ACCESS Act ---H.R.9504: Tax Exempt Hospital Transparency Act ---H.R.9599: SECURE 340B Act ---S.5244: SUSTAIN 340B Act ---Program Implementation & Oversight ---Rebate Models Accelerated Approval Artificial Intelligence (AI) Alternative Funding Programs Biosimilars ---H.R.10628/S.5571: Biosimilars Access and Affordability Act ---S.1954: Biosimilars Red Tape Elimination Act ---Interchangeability and Pharmacy Substitution Cell & Gene Therapy ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act ---H.R.7871/S.1637: MVP Act Clinical Trial Data in China Data Privacy ---H.R.8413: SECURE Data Act Diversity & Inclusion ---Decentralized Clinical Trials Drug Evaluation and Review ---FDA Hiring Flexibility Drug Importation Drug Manufacturing, Quality & Distribution ---Advanced Manufacturing ---Compounded Medicines ---Drug Shortages ---Supply Chain Integrity and Traceability Drug Patenting ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1097: Interagency Patent Coordination and Improvement Act ---Patent Thickets ---Restrictions on Intellectual Property Rights Drug Pricing ---H.R.946: ORPHAN Cures Act ---H.R.1492/S.832: Ensuring Pathways to Innovative Cures (EPIC) Act ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act ---H.R.6166: Lowering Drug Costs for American Families Act ---S.526: Pharmacy Benefit Manager Transparency Act ---S.527: Prescription Pricing for the People Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---CMMI Authority ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Most Favored Nation Drug Pricing Proposals ---Patient Cost-Sharing and Implementation ---PBM Reform Foreign Drug Data Protection Laws ---Regulatory Harmonization Medicaid ---S.526: Pharmacy Benefit Manager Transparency Act ---Alternative Payment Arrangements for Gene Therapies ---CMMI (GENEROUS Model) ---Drug Benefit Design ---Medicaid Drug Rebate Program ---Most Favored Nation in Medicaid ---Pricing and Rebates ---Value-Based Purchasing (VBP) Rule Opioid Crisis ---Coverage and Reimbursement Orphan Drug Issues ---H.R.1414: Cameron's Law ---H.R.6166: Lowering Drug Costs for American Families Act ---H.R.10359: Priority for Pediatric Cures Act ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Orphan Drug Tax Credit Pandemic Preparedness ---Drug Supply Chain Management ---Medical Countermeasure Priority Review Voucher Reauthorization ---Monoclonal Antibody Coverage and Utilization ---R&D Funding for Medical Countermeasures ---WHO Pandemic Preparedness Accord Reimbursement and Coverage of Innovative Products ---H.R.6166: Lowering Drug Costs for American Families Act ---S.864/H.R.6423: HELP Copays Act ---CMMI Authority ---Medicare Part B Physician-Administered Products ---National Coverage Determination ---Patient Cost-Sharing and Smoothing ---Protected Classes ---Support of Patient Premiums and Cost-Sharing Obligations Vaccines and Infectious Diseases ---Adult Immunization ---Countermeasures Injury Compensation Program ---Maternal Immunization ---MCM Manufacturing & Capacity ---Medical Countermeasure Priority Review Voucher Reauthorization ---Vaccine Injury Compensation Program ---Vaccine Safety and Quality ---Vaccine Safety Net and Vaccine Infrastructure ---Value of Vaccines and Vaccine Confidence
2026 · third_quarter · Pharmacy
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Medicare/Medicaid
P.L. 119-21 (H.R. 1): One Big Beautiful Bill Act; relating to Title VII, Subtitle B H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.; all provisions S. 832: EPIC Act of 2025; all provisions S. 891: Bipartisan Health Care Act; provisions related to Titles I, II, VIII, and IX General discussions related to Drug cost and pricing policy issues
Client expense: $730,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2026 · third_quarter · Pharmacy
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
| Republican |
| TN |
| Andy Harris | Republican | MD |
| Ashley Hinson | Republican | IA |
| August Pfluger | Republican | TX |
| Beth Van Duyne | Republican | TX |
| Bill Huizenga | Republican | MI |
| Brad Knott | Republican | NC |
| Brendan F. Boyle | Democratic | PA |
| Brian Jack | Republican | GA |
| Brian K. Fitzpatrick | Republican | PA |
| Bryan Steil | Republican | WI |
| Carol D. Miller | Republican | WV |
| Claudia Tenney | Republican | NY |
| Cliff Bentz | Republican | OR |
| Craig A. Goldman | Republican | TX |
| Dan Crenshaw | Republican | TX |
| David Kustoff | Republican | TN |
| David Rouzer | Republican | NC |
| Diana Harshbarger | Republican | TN |
| Donald G. Davis | Democratic | NC |
| Earl L. "Buddy" Carter | Republican | GA |
| Erin Houchin | Republican | IN |
| Gabe Evans | Republican | CO |
| J. French Hill | Republican | AR |
| James Comer | Republican | KY |
| Jared Moskowitz | Democratic | FL |
| Jefferson Shreve | Republican | IN |
| John J. McGuire III | Republican | VA |
| Juan Ciscomani | Republican | AZ |
| Julie Fedorchak | Republican | ND |
| Kat Cammack | Republican | FL |
| Kevin Hern | Republican | OK |
| Lloyd Smucker | Republican | PA |
| Mariannette Miller-Meeks | Republican | IA |
| Mark E. Amodei | Republican | NV |
| Max L. Miller | Republican | OH |
| Michael A. Rulli | Republican | OH |
| Michael Baumgartner | Republican | WA |
| Michelle Fischbach | Republican | MN |
| Mike Carey | Republican | OH |
| Mike Flood | Republican | NE |
| Mike Haridopolos | Republican | FL |
| Mike Kelly | Republican | PA |
| Mike Kennedy | Republican | UT |
| Nathaniel Moran | Republican | TX |
| Neal P. Dunn | Republican | FL |
| Nicole Malliotakis | Republican | NY |
| Pat Harrigan | Republican | NC |
| Randy K. Weber, Sr. | Republican | TX |
| Richard Hudson | Republican | NC |
| Richard McCormick | Republican | GA |
| Rick W. Allen | Republican | GA |
| Robert E. Latta | Republican | OH |
| Robert P. Bresnahan, Jr. | Republican | PA |
| Rudy Yakym III | Republican | IN |
| Russell Fry | Republican | SC |
| Scott Fitzgerald | Republican | WI |
| Scott H. Peters | Democratic | CA |
| Thomas H. Kean, Jr. | Republican | NJ |
| Tim Moore | Republican | NC |
| Troy Balderson | Republican | OH |
| Vern Buchanan | Republican | FL |
| Vince Fong | Republican | CA |
| W. Gregory Steube | Republican | FL |
| Zachary Nunn | Republican | IA |
Client expense: $2,560,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2026 · third_quarter · Pharmacy
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Pharmacy
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Health Issues
SB 864 - HELP Copays Act HR 946 - Orphan Cures Act SB 832/ HR 1492 - EPIC Act HR 1520 - Charlotte Woodward Organ Transplant Discrimination Prevention Act HR 3514 - Improving Seniors Timely Access to Care Act of 2025 SB 2426 - Equitable Community Access to Pharmacist Services Act H.R. 3826/ S.B. 1925 - Expanding Access to Diabetes Self-Management Training Act of 2025 SB 1140 - Health ACCESS Act Health Accelerating Consumers Care by Expediting Self-Scheduling Act H.R. 5256 - 340B ACCESS Act 340B Affording Care for Communities and Ensuring a Strong Safety-net Act SB 1973 - Treat and Reduce Obesity Act of 2025 SB 2761/ H.R. 5269 - Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. SB 932 - Give Kids a Chance Act of 2025 SB 339- Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act H.R. 4317- PBM Reform Act of 2025 Pharmacy Benefit Manager Reform Act of 2025 H.R. 1244 - Reducing Drug Prices for Seniors Act H.R. 8270 - Every Dollar Counts Acr of 2026 H.R. 9599 - SECURE 340B Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Pharmacy
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R.1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
Client expense: Not reported · Firm income: $60,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Essential medicines/Buy American regarding all bio-pharmaceutical provisions Discussions regarding condification of MFN policies Fixed dose conbination drugs and general research and development Prescription Information Modernization Act of 2026 (PIMA)
Client expense: $3,050,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1387: National Biotechnology Initiative Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3014: Ensuring Timely Access to Generics Act of 2025 S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act S. 3794: SAFE Drugs Act of 2026 S. 4189: INSULIN Act of 2026 S. 5043: Secure Drug Supply Chain Act of 2026 S. 5244: SUSTAIN 340B Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 3521: Clinical Trial Modernization Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 6509: SAFE Drugs Act of 2025 H.R. 6610: Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT H.R. 8269: CLEAR LABELS Act H.R. 9599: SECURE 340B Act H.R. 9661: Expedited Access to Biosimilars Act 340B Drug Pricing Integrity and Affordability for Patients Act (draft) SECURE Act of 2026 (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Peptides/counterfeiting policy issues Controlled substances policy issues Generics/devices policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B Rebate Model Pilot Program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First
Client expense: $1,530,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2026 · third_quarter · Medicare/Medicaid
Monitor and engage on legislative and administrative action related to Medicare and Medicaid policy. Monitor the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169). Monitor and engage on legislative and administrative action related to Medicare inpatient reimbursement for cell and gene therapies. H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025. H.R. 7871, Medicaid VBPs for Patients Act (MVP Act). S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025.
Client expense: $1,710,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Medicare/Medicaid
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
- H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - H.R. 929/S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, HELP Copays Act, regarding all provisions - H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act, regarding all provisions - S. 1954/ H.R. 5526 Biosimilar Red Tape Elimination Act, regarding all provisions - H.R.2527, Early Detection of Vision Impairments for Children Act of 2025, regarding all provisions - PL117-169 The Inflation Reduction Act, regarding all provisions related to drug pricing and implementation - H.R.5343/S. 1717, the Ensuring Patient Access to Critical Breakthrough Products Act of 2025, regarding all provisions - H.R.4282, Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act, regarding all provisions - S.1399 / H.R. 6197, the Health Tech Investment Act, regarding all provisions - H.R. 3521, the Clinical Trial Modernization Act, regarding all provisions - H.R. 3006 / S.1776, the Medicare Beneficiary Co-Pay Fairness Act, regarding all provisions - H.R. 3514, the Improving Seniors Timely Access to Care Act of 2025, regarding all provisions - H.R. 6549, the VA Contracting and Procurement Act, regarding all provisions - H.R. 5509 / S. 2903, Safe Step Act, regarding all provisions - H.R. 5256, 340B ACCESS Act, regarding all provisions - H.R. 7391, Community Health Center Drug Pricing Protection Act, regarding all provisions - H.R. 3953 / S. 1874 Title VIII Nursing Workforce Reauthorization Act, regarding all provisions Issues related to - direct to consumer advertising - clinical trial modernization - biosimilars - cardiovascular health - 340B and 340B Rebate Pilot - Heart Recovery Awareness Day & H.Res. 1301, designating February 20th Heart Recovery Awareness Day - MFN - Foreign Reference Pricing - CMS Outpatient Prospective Payment System rule - peripheral artery disease (PAD) - PBM and Insurer Reforms
Client expense: $2,220,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues S. 832/H.R. 1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R.1672: Maintaining Investments in New Innovation Act or the MINI Act of 2025 Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues H.R. 5391/S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act Drug cost and pricing policy issues Medicare rebate policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues
Client expense: $840,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
2026 · third_quarter · Health Issues
H.R.2223: Building Capacity for Care Act: Grans and loan guarantees to build mental health facilities. S.931: Complete Care Act: Integrating Behavioral health care into primary care H.R. 1906:Rural Wellness Act: Grants for telemedicine to provide Access to care in rural communities S. 779/H.R. 1735: EARLY Minds Act allows States to use some Mental Health Block Grant funds towards prevention and early intervention activities. H.R. 1902: HERO Act allows for the collection of data on first responder suicides to better identify and treat PTSD and combat suicide. S. 665: Fatal Overdose Reduction Act of 2025 creates hubs to treat substance use disorders. H.R. 1305: Improving Measurements for Loneliness and Isolation Act of 2025 creates a working group to better understand and define loneliness and isolation. S. 600: Supporting Adopted Children and Families Act enhances pre and post adoption services. S. 454: Gambling Addiction Recovery, Investment, and Treatment Act creates grants for state to address gambling addiction. S. 266/H.R. 929: Dr. Lorna Breen Health Care Provider Protection Reauthorization Act continues education and awareness for mental health services. H.R. 2483: SUPPORT for Patients and Communities Reauthorization Act of 2025 extends and expands grants for serious mental illness and substance use disorder. Support for the inclusion of those with lived experience on the Make America Health Again (MAHA) Commission Support for staffing levels as of 1.1.25 at HHS and SAMHSA Support for Maternal Mental Health programs and funding Support for ending Medicare's 190-day lifetime limit on inpatient psychiatric care -- H.R. 1141: Gambling Addiction Recovery, Investment, and Treatment Act authorizes grants to states and research funding to address gambling addiction. H.R. 2044: Suicide Prevention Assistance Act establishes grants for primary care offices to provide self-harm and suicide prevention services. H.R. 2223: Building Capacity for Care Act provides financial support for developing mental health and substance use disorder treatment facilities. H.R. 2305: Corrections Officer Blake Schwarz Suicide Prevention Act of 2025 establishes a grant program to fund mental health screenings and referrals for corrections officer. H.R. 2587/S.1266: Youth Mental Health Research Act establishes a collaborative research initiative within the NIH to improve youth mental health. H.R. 2630: Youth Suicide Prevention Research Act expands research focus areas on childhood suicide to include adverse childhood experiences and toxic stress. H.R. 2904: Pursuing Equity in Mental Health Act authorizes federal grants for culturally competent research, outreach, provider training, and priority support for programs. H.R. 2936: Addressing Boarding and Crowding in the Emergency Department Act allows grants for tracking hospital bed capacity and introduces pilot programs for emergency care improvements. H.R. 2957: STRONG Support for Children Act of 2025 establishes programs aimed at preventing and mitigating childhood trauma through data analysis and strategy implementation. H.R. 3103: Health Share Transparency Act of 2025 requires health care sharing ministries to disclose financial and operational information to federal agencies and enrollees. H.R. 3130: FACTS Act establishes education and public health partnerships to prevent synthetic opioid misuse among youth. H.R. 3262: NURSE Act creates grants to increase school nurses in under-resourced schools. H.R. 3266: Mental Health Infrastructure Improvement Act of 2025 provides loans to expand and improve pediatric and adult mental health and substance use disorder treatment facilities. H.R. 3420: Words Matter Act of 2025 replacing outdated and stigmatizing terms related to intellectual disabilities with more respectful language. H.R. 3505: Barriers to Suicide Act of 2025 creates a grant program to install nets and barriers on infrastructures like bridges and railroads. H.R. 3520: STAND Against Emerging Opioids Act schedules tianeptine and its analogues as Schedule III controlled substances. H.R. 3601: National ACERT Grant Program Authorization Act establishes a new grant program focused on addressing adverse childhood experiences related to trauma exposure. H.R. 3689: TREAT Youth Act reauthorizes and increases funding for youth substance use prevention and recovery initiatives under the SUPPORT for Patients and Communities Act. H.R. 3743: Supporting Healthy Mothers and Infants Act of 2025 modernizes language for substance use disorder and expands nutrition education and outreach. S. 1056: Home-Based Telemental Health Care Act of 2025 establishes a grant program to improve mental health and substance use services for rural populations through telemental health care. S. 1062: Suicide Prevention Act establishes programs to enhance surveillance of self-harm and provide suicide prevention services in hospital emergency departments. S. 1074: Agricultural Access to Substance Use Disorder Treatment and Mental Health Care Act of 2025 requires a study on the accessibility of mental health and substance use disorder services for farmers and ranchers. S. 1261: CONNECT for Health Act of 2025 seeks to expand telehealth access by removing geographic restrictions. S. 1329/H.R. 2741: PEER Support Act supports and professionalizes peer support specialists and establishes an Office of Recovery. S. 139: FASD Respect Act reauthorize and extend the Fetal Alcohol Spectrum Disorders (FASD) Prevention and Services program. S. 1448: Pursuing Equity in Mental Health Act seeks to improve mental health services and reduce disparities for racial and ethnic minority youth through increased funding, research, and education initiatives. S. 1663/H.R. 3243: Therapeutic Fraud Prevention Act of 2025 prohibits commercial conversion therapy. S. 1673/H.R. 3260: Mental Health Improvement Act extends the authorization period for mental and behavioral health education and training grants. S. 1689/ H.R. 3316: Stop Mental Health Stigma in Our Communities Act of 2025 mandates the development of a national outreach and education strategy tailored to the cultural and linguistic needs of AANHPI populations. S. 1878: ATTAIN Mental Health Act creates an online dashboard to centralize public access to information about federal and state grants for mental health and substance use disorder programs. S. 473: SENIOR Act address loneliness among older adults by requiring screenings, coordinating services, and preparing a report on loneliness. S. 931/H.R. 2509: COMPLETE Care Act incentivizes behavioral health integration with primary care through increased payments and technical assistance. S.Res. 208: A resolution supporting the designation of May 10, 2025, as "National Asian American, Native Hawaiian, and Pacific Islander Mental Health Day." S.Res. 249/H.Res. 441: A resolution expressing support for the designation of May 2025 as "Mental Health Awareness Month." H.R. 3305. Barriers to Suicide Act: Creates a grant program to provide suicide barriers on bridges and other structures H.Res 542/S. 332: Expressing support for the designation of the month of June 2025 as National Post-traumatic stress Awareness Month and June 27, 2025 as National Post-traumatic Stress Awareness Day H.Res 671: Prioritizing Mental Health to the Same Degree as Physical Health to address the epidemics of suicide and drug overdose in the United States H.Res 697/ S. Res 385: Recognizing Suicide as a serious public health problem and supporting September as National Suicide Prevention Month and September 10 as World Suicide Prevention Day H.Res 764: Recognizing the continuing disparities in Black youth mental health and access to care H.R. 4400/S. 2282: Farmers First Act: reauthorizes and expands funding of the Farm Ranch Suicide Prevention Act. HR 4723/ S.2446: Mental Health For Latinos Act: Directs the development of a culturally tailored mental health outreach and education strategy for Hispanic and Latino Populations. S. 2556: Protecting Health Care and Lowering Costs Act: repeals recent health law changes, permanently expands ACA Tax Credits beyond 400% FPL, and sets a new sliding scale for premium contributions H.Res 684: A resolution expressing support for the designation of September 9, 2025, as National Firearms Suicide Prevention Day HR 5509/S 2903: The Safe Step Act: Creates a clear process to appeal step therapy process S.2826/H.R. 5434:The 988 LGBTQ+ Youth Access Act of 2025: Mandates that at least 9% of suicide prevention hotline funding be reserved for specialized services supporting LGBTQ + youth H.R. 1492: To Amend title XI of the Social Security Act to equalize the negotiation period between small molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2085: The Mental Health Research Accelerator Act: establishes programs to speed up mental health research and innovations H.R. 3419: To Amend the Public Health Service Act to reauthorize the telehealth network and telehealth resource center grant program H.R. 4805: WINGS ACT: Requires a report on the long-term brain and mental health effects of military aviation. H.R. 5306: Gun Suicide Prevention Act of 2025: requires all firearms sold in the United States to display the suicide prevention lifeline label H.R. 5733: Community Mental Wellness Worker Training Act: establishes a grant program to train and certify community mental wellness workers H.R. 5859: Behavioral Health Crisis Care Centers Act: establishes a grant program to fund comprehensive, one stop crisis facilities H.R. 5861: Legacy Act of 2025 mandates a study on creating a secure, national system for storing and retrieving last wish documents. H.R. 6226 Latino Youth Mental Health Empowerment Act: Establish a Mental Health awareness campaign focused on Latino youth. H.R. 6817 To establish a home-based telemental health care grant program to increase mental health and substance use services for individuals in fishing, farming and forestry occupations H.Res. 792 Declaring a need for increased investment in youth mental Health and recognizing youth mental health day and youth suicide prevention day. S.2005 IDeA Reauthorization Act: Strengthens the NIH's Institutional Development Award Program S.2131/H.R. 5828 Dad's Matter Act: Requires a federal public awareness campaign and state guidance to promote fatherhood. S.2336: Halting the Epidemic of Addiction and Loss Act: Update grant program regulation and guidance to include all FDA opioid reversal agents, not just Naloxone S. 2825/H.R.5417 Health Access Innovation Act 2025: grant program to support faith and community-based organizations in addressing health inequities and chronic disease. S.3199 988 Lifeline Location Improvement Act: creates an advisory committee to study and recommend a solution for transmitting geolocation information with 988 calls. S. 3076 Nitazene Control Act: permanently classifies all nitazene opioids as schedule 1 Support for improving integrated care for those with Tardive Dyskinesia H.R. 6249: Addressing Addiction After Disasters Act expands federal disaster relief to include SUD and AUD services alongside mental health support. H.R. 6283: FOSTER Act expand opioid response grants and defines and supports kinship caregivers. H.R. 6396: Kid PROOF Act of 2025 expands grant eligibility and funding to support suicide and overdose prevention among youth. H.R. 6630: Expanding Mental Health Access for Cyber Command Personnel Act requires security-cleared behavioral health professionals to be assigned to Cyber Command locations. H.R. 6679: Tech Wellness for Young Men Act requires a study on the mental, social, and developmental impacts of screen addiction among young men. H.R. 6680: Tech Wellness for Men Act study on the economic, mental health, and social impacts of screen addiction among adult men. H.R. 6940: Hope Heals Act of 2026 requires an assessment amount Executive departments to enhance mental health. H.R. 7030: Securing Facilities for Mental Health Services Act expands access to federal mortgage insurance for all licensed hospitals, including mental health facilities. H.R. 7602: State of Men's Health Act requires a study on men's health disparities and establishes an Office of Men's Health. H.R. 8124: STOP Suicide Act creates a grant program to support evidence-based stabilization services for individuals with serious suicidal thoughts. H.R. 8149: Agricultural Access to Addiction and Mental Health Care Act mandates a study on improving access to addiction and mental health care for farmers and ranchers. H.R. 8160: Premenstrual Dysphoric Disorder Awareness and Research Act of 2026 expand research, raise awareness, improve provider education, and increase access to care for PMDD. H.R.8122: 9-8-8 Connect Act allocates $30 million for crisis center follow-up services. S. 3230: Family Caregiver Peer Support Act creates grants to expand in-person and virtual peer support programs for family caregivers. S. 3271: In-Home CARE Act authorizes grants to support family caregivers through home visiting programs. S. 3402: Ensuring Excellence in Mental Health Act expands and standardizes community behavioral health clinic services S. 3431: Improving Measurements for Loneliness and Isolation Act of 2025 establishes a working group to standardize how loneliness and isolation are defined and measured. S. 3461: RISE from Trauma Act authorizes expands and builds trauma-informed systems for youth and families affected by trauma, violence, and substance use. S. 3714: Family-to-Family Reauthorization Act of 2026 extends and specifies funding for family-to-family health information centers. S. 3840/H.R. 7496: Health Investment Zones Act of 2026 creates Health Investment Zones for incentives, grants, and support to reduce health disparities. S. 921: Tyler's Law requires a federal study and subsequent guidance on whether hospital emergency departments should routinely test for fentanyl in overdose cases. H.R. 7875: Providing Opportunities for Individuals in Need of Treatment and Support (POINTS) Act of 2026 expands prevention, treatment, and recovery services for individuals experiencing gambling addiction. S. 4001/H.R. 7828: Supplemental Security Income Restoration Act of 2026 modernizes SSI eligibility and benefit rules. ___ H.R. 7911: Dream's Caregiver Health and Wellness Act grant program for nonprofits to promote caregiver wellness through support services, mental health resources, and community-building initiatives H.R. 8201: Expanding Community Access to Health Services Act mandates that community health centers provide behavioral, mental health, and substance use disorder services as part of primary care H.R. 8209: To amend the Public Health Service Act to reauthorize the school-based health centers grant program. H.R. 8504: Rural Health Resilience Act of 2026 creates a federal loan and loan guarantee program to help financially distressed rural health centers maintain essential services and avoid closure H.R. 8743: SMART Kids Act requires the Surgeon General to develop and publish age-specific, evidence-based screen time recommendations for children H.R. 8961: Student Suicide Prevention Awareness Act of 2026 requires a coordinated public awareness campaign and updated, visible signage in schools about 988 H.R.8916: CHIERS Act of 2026 grants to fund free transportation services for vulnerable individuals to access substance use disorder treatment and supportive services H.Res.1290: Recognizing the significant and often overlooked behavioral health needs experienced by individuals and families affected by rare diseases, and for other purposes. H.Res.1327: Supporting the designation of May 2026 as "Borderline Personality Disorder Awareness Month" H.Res.1329: Expressing support for the designation of May 2026 as "Mental Health Awareness Month" S. 4149: Social Determinants for Moms Act creates a task force and grant program to coordinate and fund efforts addressing clinical and nonclinical factors contributing to maternal mortality and health disparities S. 4210/H.R. 8070: Child Suicide Prevention Act grant programs and educational initiatives to reduce suicide among individuals under 26 S. 4552: Moms Matter Act grant programs to expand maternal mental health and substance use disorder services S. 4640/H.R. 8122: 988 Connect Act expands funding and regulatory requirements to enhance follow-up care and accessibility for individuals using 988 S.Res. 710/H.Res. 1256: A resolution recognizing Maternal Mental Health Day to raise awareness about maternal mental health. S.Res. 727: A resolution supporting the designation of May 29, 2026, as "Mental Health Awareness in Agriculture Day" to raise awareness around mental health in the agricultural industry and workforce and to continue to reduce stigma associated with mental illness. S.Res.714: A resolution supporting the designation of May 10, 2026, as "National Asian American, Native Hawaiian, and Pacific Islander Mental Health Day" __ H.R. 10116: Lifeline for First Responders Act establishes a grant program to support the mental health and wellness of first responders. H.R. 10216: Public Transit Mental Health Awareness Act requires public transit agencies receiving federal funds to display suicide prevention hotline information on vehicles or in facilities. H.R. 10246: 988 Community Infrastructure Act establishes a grant program to fund capital improvements for health centers and crisis response facilities. H.R. 10280: 988 Implementation Act of 2026 comprehensive legislative proposal aimed at strengthening the behavioral health crisis response infrastructure. H.R. 10349: EMT Act establishes a federally funded fellowship program to train culturally competent mental health professionals to better serve emergency responders. H.R. 8203: Workforce Recovery and Resilience Act updates best practices and targeted grants for training and employment activities addressing substance use disorder impacts on the workforce. H.R. 8811: Moms Matter Act establishes grant programs to improve maternal mental health and substance use disorder services. H.R. 8989: Evidence-Based Youth Suicide Prevention Act of 2026 establish demonstration programs aimed at developing, implementing, and evaluating evidence-based strategies to prevent suicide among children and adolescents. H.R. 9675: Expanding Opportunities for Recovery Act of 2026 establishes a grant program to help states expand evidence-based opioid addiction treatment for uninsured and underinsured individuals. H.Res. 1503: Supporting the goals of Overdose Awareness Day and strengthening efforts to combat the opioid crisis. H.Res. 1528: Designates September, 2026, as "National Suicide Prevention Month" as well as September 10, 2026, as "World Suicide Prevention Day". H.Res. 1534: Designates the week of September 13 to 19, 2026, as "National Co-Responder and Crisis Clinician Week". S. 3924/H.R. 10193: We Can't Wait Act of 2026 allows disabled individuals to opt for early receipt of Social Security disability benefits during the waiting period with a slightly reduced monthly amount. S. 4503: Advancing Menopause Care and Mid-Life Women's Health Act directs investment and coordination to advance research, care, education, and public health initiatives for menopause. S. 4816: Addressing SILO Act of 2026 establishes a grant program to reduce social isolation and loneliness among older adults and adults with disabilities. S. 5137/H.R. 9866: CARE for Mental Health Professionals Act creates a grant program to support interstate licensure compacts for mental health professionals. S. 5207: RCORP Authorization Act establish and maintain RCORP under HRSA. S. 5263: Workforce Recovery and Resilience Act amends the WIOA to address the workforce impacts of substance use disorders. S. 5327: Constructing the Path to Suicide Prevention Act mandates a federal study of suicide risk factors among construction workers. S. 5365: Community Mental Wellness Worker Training Act establishes a grant program to train and certify community mental wellness workers. S. 5425: Addiction Grants Modernization Act establishes a centralized, streamlined application process for federal discretionary substance use disorder grant programs. S. 5558: Barriers to Suicide Act of 2026 establishes a grant program for installing evidence-based suicide deterrents on key infrastructure. S.Res. 770: A resolution designating June 6, 2026, as National Naloxone Awareness Day. S.Res. 853/H.Res. 1514: A resolution expressing support for the designation of September 8, 2026, as 988 Day.
Client expense: $10,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), President of the U.S., SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2026 · third_quarter · Medicare/Medicaid
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client expense: $1,020,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing
Client expense: $940,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2026 · third_quarter · Health Issues
Medicare Part D, Medicare Part B Issues, Importation of Drugs; H.R. 1, the One Big Beautiful Bill Act; H.R. 1492, S. 832, the EPIC Act; Medicare IRA implementation, Drug Premium Stabilization Program. Drug pricing, reimbursement and coverage related to MFN including CMMI models, 340B, IRA maximum fair price, ASP. PBM Reform included in H.R. 7194, the Consolidated Appropriations Act, the Department of Labor proposed PBM rule. Affordability and patient access issues; EPIC
Client expense: Not reported · Firm income: $90,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), White House Office
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies and affordability Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act
Client expense: $880,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Pharmacy
H.R.1672 - Maintaining Investment in New Innovation Act - All Provisions H.R.1492/S.832 - EPIC Act of 2025 - Discussion around encouraging innovation and research transparency for rare disease drugs.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267) Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Accelerating Kids Access to Care Act (HR 1509, S 752), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.
Client expense: $440,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Mikaela Naylon Give Kids A Chance Act (HR 1262), Give Kids A Chance Act (S 932), Cameron's Law (HR 1414), Kids Access to Care Act (Accelerating HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 1930), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), BINSA Act, H.R. 9102, Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.
Client expense: $440,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to coverage of anti-obesity medications. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
2026 · third_quarter · Medicare/Medicaid
Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.
Client expense: Not reported · Firm income: $70,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, White House Office
2026 · third_quarter · Health Issues
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Pharmacy
Prescription drug pricing policy. H.R.1492 - Ensuring Pathways to Innovation Cures (EPIC) Act. ORPHAN Cures Act. MINI Act. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act. H.R.7391 - Community Health Center Drug Pricing Protection Act. H.R.5509 - Safe Step Act. Clinical Trial Modernization Act. Essential medicines/Buy American. Issues related to the 340B Drug Pricing Program. International Reference Pricing/Most Favored Nation.
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Pharmacy
Pharmaceutical Supply Chain. H.R.2213: Medical Supply Chain Resiliency Act. Issues related to the 340(b) program. H.R.1492/S.832: EPIC Act of 2025.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; CMMI Drug Pricing Demonstration Programs; drug pricing; Valued-Based Payments; H.R.1492/S.832, EPIC Act of 2025; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Pharmacy
Pharmacy Benefit Manager (PBM) issues and reform. 340B. IRA implementation. H.R.1492: Ensuring Pathways to Innovative Cures (EPIC) Act. Drug pricing. Most-Favored Nation (MFN) International reference pricing. H.R.5378 - Lower Costs, More Transparency Act. H.R.5376 - Share the Savings with Seniors Act. H.R.6283/S.1542 - DRUG Act. H.R.830 - HELP Copays Act. Global Benchmark for Efficient Drug Pricing (GLOBE) Model.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
Issues pertaining to the implementation of the Inflation Reduction Act of 2022 - H.R. 6166, Lowering Drug Costs for American Families Act Issues pertaining to CMS Coverage of APS in LTC Issues pertaining to Medicares Six Protected Classes policy Medicare Part D Smoothing Benefit - FY 2026 and FY2027 Labor-HHS Appropriations Orphan drug exclusion in the Inflation Reduction Act - H.R. 946 & S. 1862, ORPHAN Cures Act Small molecule discrepancy in the Inflation Reduction Act - H.R. 1492 & S. 832, The EPIC Act Issues pertaining to the Most Favored Nation drug price setting policy - H.R. 7837, Most Favored Patient Act of 2026 Issues pertaining to migraine screening for women in Medicare - FY 2026 and FY2027 Labor-HHS Appropriations Issues pertaining to prior authorization - HR 3514, Improving Seniors Timely Access to Care Act
Client expense: $130,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Monitoring healthcare legislation. Education regarding market based solutions to bring down the cost of drug prices. Education regarding the dangers of global counterfeit medications. Education regard the International Pricing Index (IPI) Model, which would import single-payer government run price controls that limit innovation and patient access to life saving therapies. Support for PBM reform. HR 2214 -- "DRUG Act" HR 1492 -- "To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program." S.832 - "EPIC Act of 2025." Education regarding the Most Favored Nation Executive Order. Support the 340B CMS pilot program. HR 7391 "Community Health Center Drug Pricing Protection Act."
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Pharmacy
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Client expense: $180,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Pharmacy
Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing and price controls, supply chain issues, pharmacy benefit managers transparency issues, intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act"; S. 3345, "PBM Price Transparency and Accountability Act"; S. 2658, Medication Affordability and Patent Integrity Act; S. 1414, Expedited Access to Biosimilars Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Insurance
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Pharmacy
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Trade (domestic/foreign)
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Financial Institutions/Investments/Securities
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Economics/Economic Development
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Medicare/Medicaid
Monitor and engage on legislative and administrative action related to Medicare and Medicaid policy. Monitor the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169). H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025. S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025.
Client expense: $2,040,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · second_quarter · Medicare/Medicaid
P.L. 119-21 (H.R. 1): One Big Beautiful Bill Act; relating to Title VII, Subtitle B H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.; all provisions S. 832: EPIC Act of 2025; all provisions S. 891: Bipartisan Health Care Act; provisions related to Titles I, II, VIII, and IX General discussions related to Drug cost and pricing policy issues
Client expense: $700,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2026 · second_quarter · Medicare/Medicaid
FY 2026 Appropriations for Specific Issues ---Alternative Funding Programs ---Antimicrobial Resistance (General) ---CMMI: GLOBE and GUARD Models ---Drug Pricing ---Pandemic Preparedness - R&D Funding for Medical Countermeasures ---Vaccines and Infectious Diseases 340B Drug Discount Program ---H.R.5256: 340B ACCESS Act ---H.R.9504: Tax Exempt Hospital Transparency Act ---Program Implementation & Oversight ---PROTECT 340B Act ---Rebate Models ---SECURE 340B Act ---SUSTAIN 340B Act Alternative Funding Programs Biosimilars ---Biosimilars Red Tape Elimination Act ---Interchangeability and Pharmacy Substitution Cell & Gene Therapy ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act Clinical Trial Data in China Data Privacy ---H.R.8413: SECURE Data Act Drug Manufacturing, Quality & Distribution ---Advanced Manufacturing ---Compounded Medicines ---Drug Shortages ---Supply Chain Integrity and Traceability Drug Patenting ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1097: Interagency Patent Coordination and Improvement Act ---Patent Thickets ---Restrictions on Intellectual Property Rights Drug Pricing ---H.R.1492: Ensuring Pathways to Innovative Cures (EPIC) Act ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act ---H.R.5391/S.2764: Protecting Patient Access to Cancer and Complex Therapies Act ---S.526: Pharmacy Benefit Manager Transparency Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---CMMI: GLOBE and GUARD Models ---CMMI Authority ---Implementation of ORPHAN Cures Act ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Most Favored Nation Drug Pricing Proposals ---Patient Cost-Sharing and Implementation ---PBM Reform ---Strengthening Innovation in Medicare and Medicaid Act Foreign Drug Data Protection Laws Medicaid ---S.526: Pharmacy Benefit Manager Transparency Act ---Alternative Payment Arrangements for Gene Therapies ---CMMI (GENEROUS Model) ---CMMI: GLOBE and GUARD Models ---Drug Benefit Design ---Medicaid Drug Rebate Program ---Most Favored Nation in Medicaid ---Pricing and Rebates ---Value-Based Purchasing (VBP) Rule National Defense ---National Defense Authorization Act of 2027 Opioid Crisis ---Non-Opioid Analgesics Orphan Drug Issues ---Implementation of ORPHAN Cures Act ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Pediatric Priority Review Voucher Program Reauthorization Precision Medicine Initiative Reimbursement and Coverage of Innovative Products ---S.864/H.R.6423: HELP Copays Act ---CMMI Authority Vaccines and Infectious Diseases ---Adult Immunization ---Countermeasures Injury Compensation Program ---MCM Manufacturing & Capacity ---Medical Countermeasure Priority Review Voucher Reauthorization ---Vaccine Injury Compensation Program ---Vaccine Safety and Quality ---Value of Vaccines and Vaccine Confidence
Client expense: $2,360,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. H.R.4317, PBM Reform Act of 2025 S.3345, PBM Price Transparency and Accountability Act H.R.6837, to amend the Emloyee Retirement Income Security Act of 1974 to ensure PBMs are considered fiduciaries Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act
Client expense: $1,060,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.7391, CHC Drug Pricing Protection Act H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Essential medicines/Buy American regarding all bio-pharmaceutical provisions
Client expense: $3,160,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medicare/Medicaid
Monitor and engage on legislative and administrative action related to Medicare and Medicaid policy. Monitor the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169). Monitor and engage on legislative and administrative action related to Medicare inpatient reimbursement for cell and gene therapies. H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025. S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025.
Client expense: $1,820,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · second_quarter · Health Issues
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · second_quarter · Health Issues
- H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - H.R. 929/S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, HELP Copays Act, regarding all provisions - H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act - S. 1954/ H.R. 5526 Biosimilar Red Tape Elimination Act, regarding all provisions - H.R.2527, Early Detection of Vision Impairments for Children Act of 2025, regarding all provisions - PL117-169 The Inflation Reduction Act, regarding all provisions related to drug pricing and implementation - H.R.5343/S. 1717, the Ensuring Patient Access to Critical Breakthrough Products Act of 2025, regarding all provisions - H.R.4282, Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act, regarding all provisions - S.1399 / H.R. 6197, the Health Tech Investment Act, regarding all provisions - H.R. 3521, the Clinical Trial Modernization Act, regarding all provisions - H.R. 3006 / S.1776, the Medicare Beneficiary Co-Pay Fairness Act, regarding all provisions - H.R. 3514, the Improving Seniors Timely Access to Care Act of 2025, regarding all provisions - H.R. 6549, the VA Contracting and Procurement Act, regarding all provisions - H.R. 5509 / S. 2903, Safe Step Act, regarding all provisions - H.R. 5256, 340B ACCESS Act, regarding all provisions - H.R. 7391, Community Health Center Drug Pricing Protection Act, regarding all provisions Issues related to - direct to consumer advertising - clinical trial modernization - biosimilars - cardiovascular health - 340B and 340B Rebate Pilot - Heart Recovery Awareness Day & H.Res. 1301, designating February 20th Heart Recovery Awareness Day - obesity treatments - MFN - Foreign Reference Pricing - CMS Outpatient Prospective Payment System rule - peripheral artery disease (PAD) - PBM and Insurer Reforms
Client expense: $1,440,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office